In a statistical analysis, Brukinsa resulted in fewer cases of disease progression or death and resulted in lower overall healthcare costs than Imbruvica in patients with chronic lymphocytic leukemia.

In our “Why I'm Running” series, Boston Marathon runners share what's inspiring them to make the 26.2-mile trek from ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

and administration guidelines for each medication. A dedicated FAQ section is available for common drugs to address questions and provide a deeper understanding of Leukemia management options.

Further, compared to insulin use, GLP-1RA use was associated with a significantly reduced risk of lymphoid leukemia, myeloid leukemia, MPN, MDS, amyloidosis, non-Hodgkin lymphoma, monoclonal ...

Diana Divito, a cancer patient from Pennsylvania, was paying more than $800 per month for her leukemia medication. “I almost had a heart attack when I saw the first copay,” she recalled.

Recent studies suggest that a proportion of chronic myeloid leukemia (CML) patients in deep molecular remission can discontinue the tyrosine kinase inhibitor (TKI) treatment without disease relapse.

A graphic showing, top to bottom, how DNA aptamers target two specific markers on a leukemia stem cell’s surface, enter the cell and deliver anticancer drugs, resulting in death of the cancer cell.